Home | Site Map | Contact Us | Bookmark
 
  Single Disease Educational Content
  Multi-Disease
Educational Content
  Other Resources
  About CLDF
 
 

Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Fatty Liver Disease (NAFLD)
  Additional content on this specific disease state can be found in the:   Click on another disease specific
area listed above to view content
 

Liver News Library
 
 
 
 

NASH/NAFLD Slide Archive

  
 
   
Natural History  
Diagnosis  
Relationship to Obesity & the Metabolic Syndrome  
Treatment  
Clinical Presentation  
Epidemiology  
Obesity in the U.S.  
Pathogenesis  
 
     
     
 
  1. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B
    Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS; National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Liver Transpl. 2009 Sep;15(9):1010-20.

  2. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
    Williams CD, Stengel J, Asike MI et al. Gastroenterol 2011;140(1):124-131.

  3. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection
    Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz e117. Epub 2010 Aug 14.

  4. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
    Williams CD, Stengel J, Asike MI et al. Gastroenterol 2011;140(1):124-131.

  5. Non-alcoholic fatty liver disease: The mist gradually clears
    De Alwis NM, Day CP. J Hepatol 2008;48:S104-S112.

  6. Modest Wine Drinking and Decreased Prevalence of Suspected Nonalcoholic Fatty Liver Disease
    Dunn W, Xu R, and Schwimmer J. HEPATOLOGY 2008;47:1947-1954.

  7. A Clinical Scoring System for Predicting Nonalcoholic Steatohepatitis in Morbidly Obese Patients
    Campos G, Rambha K, Vittinghoff E, Rabl C, Posselt A, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass N, and Merriman R. HEPATOLOGY 2008;47:1916-1923.

  8. Rosiglitazone: Possible complications and treatment of non-alcoholic steatohepatitis (NASH)
    Henriksen J, Ring-Larsen H.. J of Hepatology 2008;48:174-176.

  9. Fibrosis in Genotype 3 Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease: Role of Insulin Resistance and Hepatic Steatosis
    Bugianesi E, Marchesini G, Gentilcore E, Cua I, Vanni E, Rizzetto M, George J. Hep 44:1648-1655

  10. Similarities and Differences in Outcomes of Cirrhosis Due to Nonalcoholic Steatohepatitis and Hepatitis C
    A Sanyal et al. HEP Vol 43, No 4 (April) 2006: 682-689
   

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2011 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource
for US healthcare providers only. Use of this Web site is governed by the CLD Foundation terms of use and privacy statement.